Jeffrey Weitz chercheur
Weitz, Jeffrey I.
Weitz, Jeffrey I., 19..-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Weitz, Jeffrey
VIAF ID: 2290148209305100460005 (Personal)
Permalink: http://viaf.org/viaf/2290148209305100460005
Preferred Forms
-
100 0 _
‡a
Jeffrey Weitz
‡c
chercheur
-
100 1 _ ‡a Weitz, Jeffrey
-
100 1 _ ‡a Weitz, Jeffrey
-
100 1 _
‡a
Weitz, Jeffrey I
-
100 1 _ ‡a Weitz, Jeffrey I
-
100 1 _ ‡a Weitz, Jeffrey I.
-
100 1 _ ‡a Weitz, Jeffrey I.
-
100 1 _ ‡a Weitz, Jeffrey I.
-
100 1 _
‡a
Weitz, Jeffrey I.
-
100 1 _
‡a
Weitz, Jeffrey I.
-
100 1 _ ‡a Weitz, Jeffrey I.
-
100 1 _
‡a
Weitz, Jeffrey I.,
‡d
19..-....
4xx's: Alternate Name Forms (8)
Works
| Title | Sources |
|---|---|
| Hematology : basic principles and practice |
|
| Impact of concomitant antiplatelet therapy on the efficacy and safety of DOACs for acute venous thromboembolism: systematic review and meta-analysis |
|
| Importance of family history as a risk factor for venous thromboembolism. |
|
| In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding. |
|
| In the presence of phospholipids, glycosaminoglycans potentiate factor Xa-mediated protein C activation by modulating factor Xa activity |
|
| Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study |
|
| Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation |
|
| Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin |
|
| Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen. |
|
| Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats |
|
| Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial |
|
| Inhibition of osteolytic bone metastasis by unfractionated heparin |
|
| Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry |
|
| Letter to the Editor: Managing Dabigatran-Related Bleeding |
|
| Leukocyte urokinase plasminogen activator receptor and PSGL1 play a role in endogenous arterial fibrinolysis |
|
| Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin. |
|
| Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial |
|
| Long range communication between exosites 1 and 2 modulates thrombin function |
|
| Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials |
|
| Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis |
|
| Low-dose warfarin in rehabilitating stroke survivors |
|
| Lubricant-Infused PET Grafts with Built-In Biofunctional Nanoprobes Attenuate Thrombin Generation and Promote Targeted Binding of Cells |
|
| Lubricant-Infused Surfaces with Built-In Functional Biomolecules Exhibit Simultaneous Repellency and Tunable Cell Adhesion |
|
| Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. |
|
| MAA868 locks factor XIa in a zymogen-like state |
|
| Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease |
|
| Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done? |
|
| Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo |
|
| Mechanisms Responsible for Catalysis of the Inhibition of Factor Xa or Thrombin by Antithrombin Using a Covalent Antithrombin-Heparin Complex |
|
| Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation |
|
| Meeting the unmet needs in anticoagulant therapy |
|
| Modes and consequences of thrombin's interaction with fibrin |
|
| Modification of polyurethane with polyethylene glycol-corn trypsin inhibitor for inhibition of factor Xlla in blood contact |
|
| More on Acutely Injured Patients Receiving Dabigatran |
|
| Mortality Risk Profiles for Sepsis: A Novel Longitudinal and Multivariable Approach |
|
| Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation |
|
| Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms |
|
| New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy |
|
| New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin |
|
| New developments in anticoagulants: Past, present and future |
|
| New oral anticoagulants: which one should my patient use? |
|
| NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank |
|
| Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology |
|
| North American Thrombosis Forum, AF Action Initiative Consensus Document |
|
| Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillation |
|
| A novel approach to thrombin inhibition |
|
| Novel oral anticoagulants and reversal agents: Considerations for clinical development |
|
| Novel oral anticoagulants in gastroenterology practice |
|
| OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux? |
|
| Obituary for Dr. Clive Kearon |
|
| An omniphobic lubricant-infused coating produced by chemical vapor deposition of hydrophobic organosilanes attenuates clotting on catheter surfaces |
|
| Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis |
|
| An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery |
|
| Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants |
|
| Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease |
|
| Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study |
|
| Orally active direct thrombin inhibitors |
|
| Otamixaban in acute coronary syndromes |
|
| Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. |
|
| Overview of the new oral anticoagulants: opportunities and challenges |
|
| Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis |
|
| Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
|
| Patients with severe sepsis vary markedly in their ability to generate activated protein C |
|
| Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial |
|
| Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran |
|
| Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation |
|
| A PoTENtial Antidote: A Prohemostatic Factor Xa Variant for Reversal of Direct Oral Anticoagulants |
|
| A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial. |
|
| A Test in Context: D-Dimer |
|
